Oct 24, 2024 / 09:00AM GMT
Simon Ãstergaard CellaVision AB-President and CEO
Thank you very much. And thank you to everybody dialing in to listen in on our comments and presentation of the Q1 report here in our 50-year 2024.
I have our CFO magnus split with me and we're happy to share all the insights that we just published this morning.
So we can go to the first slide where we talk about the quarter in brief. So Q3, we have designated the, the title to the report, Strong Sales in India aid market uncertainties. So, I would say the quota has been characterized by a reasonable Q3. Also, historically, it's not our strongest quota. However, the fluctuations amongst the different regions are distinct. So, we have seen really benefited from very strong growth across multiple markets, but also across essentially all product groups. And then we are up against a weak compare, a favorable compare if you like from, from last year.
Sales have declined in Americas.
We've seen uncertainties play out in the clinical settings around in the hospital environment. So, delays of both
Q3 2024 CellaVision AB Earnings Call Transcript
Oct 24, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers